The data underlying the findings cannot be made freely available because of ethical and legal restrictions. This is because the present study includes an important number of variables that, together, could be used to re-identify the participants based on a few key characteristics and then be used to have access to other personal data. Therefore, the French National Data Safety Authority (CNIL) strictly forbids making such data freely available. However, they can be obtained upon request from the JUMODA steering committee. Readers may contact: <diane.korb@inserm.fr> or <epope@inserm.fr> to request the data.

Introduction {#sec005}
============

Twin pregnancies account for about 3% of all births in the United States and France \[[@pone.0229612.ref001],[@pone.0229612.ref002]\]. Compared with women with singleton pregnancies, women with twin pregnancies have a fourfold increased risk of developing severe acute maternal complications, mainly during the intra and postpartum periods \[[@pone.0229612.ref003]\]. However this overall risk augmentation may actually vary by subgroups of women.

Risk factors of severe acute maternal morbidity in women carrying twins have been poorly characterized because previous studies, sparse and old, used variable definitions of maternal morbidity or lacked a specific control group, adequate sample size, and individual data for adjustment \[[@pone.0229612.ref004],[@pone.0229612.ref005]\]. Moreover, extrapolation to twin pregnancies of risk factors identified in singleton ones might be inappropriate. Indeed, since twin pregnancy itself constitutes a high risk clinical context, its presence could modify the profile of other risk factors. Therefore, studies of the risk factors of severe acute maternal morbidity in the specific population of twin pregnancies are needed. Understanding which subgroups are at highest risk of severe acute maternal morbidity would be useful in both counseling women and for clinicians to be alert for early recognition and treatment should an event occur to limit its severity.

Because the JUmeaux MODe d'Accouchement (JUMODA) prospective cohort collected detailed individual data in a large population of twin pregnancies, it offered the opportunity to determine risk factors of severe acute maternal morbidity in women with twin pregnancies and identify subgroups at high risk \[[@pone.0229612.ref006]\].

Materials and methods {#sec006}
=====================

The JUMODA national, observational, prospective, population-based cohort study of twin deliveries took place in France from February 10, 2014, through March 1, 2015 \[[@pone.0229612.ref006]\]. All French maternity units performing more than 1500 annual deliveries were invited to participate, regardless of their academic, public, or private status or level of care, and 176 of the 191 eligible units (92%) agreed. Women who gave birth at or after 22 weeks of gestation were included (n = 8823). Enrolment took place prospectively immediately after delivery.

Detailed information about the participating women and maternity units has been already reported elsewhere \[[@pone.0229612.ref006]\]. Research nurses collected data about maternal characteristics, medical history, pregnancy complications, maternal complications, neonatal health, and maternity unit characteristics.

The primary outcome was a composite of severe acute maternal morbidity. This multicriteria definition was developed in a formal national Delphi expert consensus process for another study specifically conducted to define and study it ([S1 Table](#pone.0229612.s001){ref-type="supplementary-material"}) \[[@pone.0229612.ref003],[@pone.0229612.ref007]\]. To include conditions involving severe health impairments, it combined diagnoses, organ dysfunctions, and interventions, as recommended by WHO \[[@pone.0229612.ref008]\]. Severe acute maternal morbidity was therefore defined as one or more of the following: maternal death; severe haemorrhage, defined by need for second line therapy, transfusion ≥ 4 units of packed red blood cells, uterine artery embolization, vascular ligation, compressive uterine suture, emergency peripartum hysterectomy; eclampsia; preeclampsia responsible for induced preterm delivery before 32 gestational weeks mainly for the mother\'s health; pulmonary embolism; stroke or cerebral transient ischemic attack; severe psychiatric disorder; cardiovascular or respiratory dysfunction, renal dysfunction (creatininemia \>1.47 mg/dL or oliguria \<500 mL/24 h), neurological dysfunction (coma of any stage and duration), or hematological dysfunction (thrombocytopenia \<50 000/mm^3^ or acute anemia \<7 g/dL, in the absence of a chronic disorder); emergency surgery in addition to the childbirth procedure, e.g., secondary hysterectomy, laparotomy for a post-delivery complication other than hematoma or wound infection; admission to an intensive care unit (ICU). This primary outcome was treated as a binary variable.

The incidence of severe acute maternal morbidity was calculated, with its 95% confidence interval, as the number of women with a severe acute maternal morbidity event, divided by the total number of pregnancies ending in still- or live birth at or after 22 weeks of gestation in the JUMODA cohort. Among women with such an event, we described the distribution of the underlying causal conditions.

The characteristics of women and of their pregnancies that we tested as potential risk factors for severe acute maternal morbidity were selected from the literature and analyzed in two steps. First, we included only characteristics known at the beginning of pregnancy that might identify women at high risk of severe acute maternal morbidity and thus potentially improve their orientation and initial care. Second, because clinical situations may change significantly during pregnancy, we integrated the information collected over its course about potential complications that might constitute additional risk factors.

The characteristics analyzed as risk factors at the beginning of pregnancy were maternal age, maternal country of birth, prepregnancy body mass index, *preexisting* insulin-treated diabetes, preexisting hypertension, other preexisting chronic conditions, parity, previous caesarean delivery, mode of conception, and chorionicity. To identify risk factors for severe acute maternal morbidity and calculate adjusted relative risks (RR) with their 95% confidence intervals (CI), we used a multivariate Poisson regression model with a random intercept to take variability between centers into account. We then used the classification and regression tree (CART) descriptive and non-explanatory approach, \[[@pone.0229612.ref009],[@pone.0229612.ref010]\] that is, we performed a CART analysis of the risk factors identified in the multivariate analysis to define and rank the factors most predictive of the risk of severe acute maternal morbidity and to individualize high-risk clinical subgroups. CART is a recursive partitioning statistical method that examines the dataset to find the best variables for grouping the women with and without severe acute maternal morbidity. Factors that are both frequent and discriminating rise in importance and result in groupings that bear resemblance and relevance to clinical practice. Among all the variables considered, CART selected the single factor that best separated the women with and without severe acute maternal morbidity to form the first node. The same procedure was then applied to each "child" node, which found the next most discriminating factor. For each node of the tree, we calculated the confidence interval of the severe acute maternal morbidity rate.

To identify the risk factors arising during pregnancy and therefore high-risk subgroups at the end of pregnancy, we repeated these statistical analyses (multivariate Poisson regression and CART analysis), adding the following variables: *gestational* insulin-treated diabetes, gestational hypertension, non-severe preeclampsia, placenta praevia, twin-to-twin transfusion syndrome, premature rupture of membranes, macrosomia for either twin (birth weight \> 95^th^ percentile of the distribution of birth weights in this cohort), and hospital characteristics, including annual volume of twin deliveries and level of care.

Two sensitivity analyses were performed. First, in order to evaluate if non-severe preeclampsia is a risk factor of severe acute maternal morbidity events other than severe hypertensive complications and to evaluate if it is a discriminant factor in CART analysis not only because severe preeclampsia is part of the severe acute maternal morbidity definition, we excluded cases of severe acute maternal morbidity only due to hypertensive complications. Second, to explore whether the associations found for characteristics present at the end of pregnancy may be due to differences in subsequent delivery context, we conducted an additional analysis of risk factors also including delivery-related characteristics, i.e gestational age at and mode of delivery. For this analysis, we excluded the severe acute maternal morbidity events before labor (antepartum, n = 32) or at an unknown time (n = 2), since those could not have been caused by delivery.

The proportion of women with missing data for any covariate included in the main multivariate model ranged from 0% to 11.4%. There were 7438 (84.3%) women with no missing data, 1201 (13.6%) with only one missing data item, and 184 (2.1%) with at least two missing items for covariates included in the multivariate model. Characteristics of the women with full data were similar to those with missing data (data not shown). We used multiple imputation-chained equations to impute missing data and generated 16 independent imputation data sets.

STATA 13 software (StataCorp LP, College Station, TX) was used for the descriptive and multivariate analyses. R Software Package (The R Foundation for Statistical Computing) was used for the CART analysis, in particular, the "rpart" R package.

The national data protection authority (CNIL, DR-2013-528), the consultative committee on the treatment of information on personal health data for research purposes (13--298), and the committee for the protection of people participating in biomedical research of Paris Ile-de-France 7 (PP-13-014) all approved this study. They approved that this observational study waived the need to obtain written informed consent according to the French law.

Results {#sec007}
=======

Among the 8823 women with twin pregnancies, 542 developed severe acute maternal morbidity, for a global incidence of 6.14% (95% CI, 5.64--6.64).

The main underlying causal condition of severe acute maternal morbidity was severe postpartum haemorrhage, accounting for 77.5% (n = 420, 4.76/100 twin pregnancies) of these cases ([S2 Table](#pone.0229612.s002){ref-type="supplementary-material"}). Admission to an ICU occurred in 22.3% (n = 121, 1.37/100 twin pregnancies). One woman in the cohort died of acute cardiac arrhythmia before labor, at 32 weeks of gestation.

Patient characteristics are presented in [Table 1](#pone.0229612.t001){ref-type="table"}, with the severe acute maternal morbidity rate by maternal characteristics.

10.1371/journal.pone.0229612.t001

###### Risk of severe acute maternal morbidity according to characteristics of the mother, pregnancy, labor, and delivery.

![](pone.0229612.t001){#pone.0229612.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                               Overall\         Women with SAMM\   Rate of SAMM per 100 twin pregnancies
                                                                               JUMODA cohort\   n                  
                                                                               n (col %)                           
  ---------------------------------------------------------------------------- ---------------- ------------------ -------------------------------------------
  Overall                                                                      8823 (100.0)     542                6.14[\*](#t001fn001){ref-type="table-fn"}

  Age (mean ± SD, years)                                                       31.6±5.4                            

      \<30                                                                     3121 (35.4)      184                5.90

       \[30--35\[                                                              3225 (36.6)      200                6.20

       \[35--40\[                                                              1806 (20.5)      90                 4.98

      ≥40                                                                      671 (7.6)        68                 10.13

  Country of birth:                                                                                                

      Europe                                                                   6373 (81.5)      376                5.90

      North Africa                                                             848 (10.8)       58                 6.84

      Sub-Saharan Africa                                                       476 (6.1)        37                 7.77

      Other                                                                    124 (1.6)        10                 8.06

  BMI before pregnancy (mean ± SD,Kg.m-2)                                      24.1±5.1                            

      \<18.5                                                                   562 (6.7)        39                 6.94

       \[18.5--24.9\]                                                          5054 (60.0)      328                6.49

       \[25--29.9\]                                                            1763 (20.9)      99                 5.62

       \[30--34.9\]                                                            696 (8.3)        34                 4.89

      ≥35                                                                      344 (4.1)        16                 4.65

  Parity and previous caesarean                                                                                    

      Nulliparous                                                              4204 (47.8)      323                7.68

      Parous with no previous caesarean                                        3535 (40.2)      154                4.36

      Parous with previous caesarean                                           1057 (12.0)      62                 5.87

  Smoking during pregnancy                                                     1280 (15.0)      55                 4.30

  Preexisting insulin-treated diabetes                                         53 (0.6)         7                  13.21

  Preexisting chronic hypertension                                             97 (1.1)         7                  7.22

  Other preexisting chronic condition[\*\*](#t001fn002){ref-type="table-fn"}   665 (7.6)        46                 6.92

  Mode of conception                                                                                               

      Spontaneous                                                              5890 (67.3)      311                5.28

      Ovulation-inducing drugs alone                                           854 (9.8)        53                 6.21

      In vitro fertilization with autologous oocytes                           1675 (19.1)      128                7.64

      Oocyte donation                                                          329 (3.8)        46                 13.98

      Chorionicity:                                                                                                

      Dichorionic                                                              6992 (79.7)      445                6.36

      Monochorionic                                                            1781 (20.3)      95                 5.33

  Insulin-treated gestational diabetes                                         325 (3.7)        23                 7.08

  Twin-to-twin transfusion syndrome                                            250 (2.8)        11                 4.40

  Gestational hypertension                                                     502 (5.7)        61                 12.15

  Non-severe preeclampsia                                                      871 (9.9)        132                15.15

  Placenta praevia                                                             72 (0.8)         16                 22.22

  Premature rupture of membranes                                               797 (9.1)        33                 4.14

  Preterm labor                                                                2881 (32.8)      167                5.80

  Gestational age at delivery (weeks days) (mean)                              35 5/6                              

      \<32 0/7                                                                 895 (10.2)       57                 6.37

      32 0/7-34 6/7                                                            849 (9.7)        43                 5.06

      35 0/7-36 6/7                                                            3047 (34.6)      178                5.84

      37 0/7-38 6/7                                                            3492 (39.7)      230                6.59

      ≥ 39 0/7                                                                 512 (5.8)        30                 5.86

  Mode of delivery[\*\*\*](#t001fn003){ref-type="table-fn"}:                                                       

      Vaginal for both twins                                                   4216 (47.9)      185                4.39

      Caesarean before labor                                                   3511 (39.9)      257                7.32

      Caesarean during labor                                                   1072 (12.2)      96                 8.96

  Macrosomia for either twin[\*\*\*\*](#t001fn004){ref-type="table-fn"}        575 (6.5)        60                 10.43

  Annual volume of twin deliveries:                                                                                

      \<50                                                                     2941 (33.3)      153                5.20

       \[50--99\]                                                              2538 (28.8)      149                5.87

      ≥100                                                                     3344 (37.9)      240                7.18

  Level of care:                                                                                                   

      I                                                                        152 (1.7)        4                  2.63

      II                                                                       3316 (37.6)      168                5.07

      III                                                                      5355 (60.7)      370                6.91
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

\* 95% confidence interval (CI) 5.6--6.6

\*\* Other preexisting chronic condition, defined by a binary variable as the presence of at least one of the following: non-insulin-treated diabetes, disease of the circulatory, respiratory, or digestive system, hematological, mental, liver, or autoimmune disease, venous thromboembolism, epilepsy, nephropathy, multiple sclerosis, neoplasia, HIV infection, or active hepatitis B or C

\*\*\* Only one mode of delivery was considered for each woman---that of the second twin in case of discrepancy between the twins

\*\*\*\* macrosomia defined as a birth weight ≥ 95th percentile of the distribution of birth weights in the JUMODA cohort

SAMM, severe acute maternal morbidity

BMI, Body mass index

SD, standard deviation

At the beginning of pregnancy, the risk factors for severe acute maternal morbidity identified in the multivariate analysis were maternal birth in sub-Saharan Africa (aRR, 1.6, 95% CI, 1.1--2.3), nulliparity (aRR, 1.6, 95% CI, 1.3--2.0), preexisting insulin-treated diabetes (aRR, 2.2, 95% CI, 1.1--4.4), and IVF with either autologous oocytes (aRR, 1.3, 95% CI, 1.0--1.6) or oocyte donation (aRR, 2.0, 95% CI, 1.4--2.8) ([Table 2](#pone.0229612.t002){ref-type="table"}). Notably, maternal age, body mass index, and chorionicity were not significantly associated with the risk of severe acute maternal morbidity in women with twin pregnancies after adjustment for the other covariates. Among risk factors present at the beginning of pregnancy, CART analysis showed that oocyte donation was the most discriminating (position A, [Fig 1](#pone.0229612.g001){ref-type="fig"}). In the absence of oocyte donation, the severe acute maternal morbidity rate was 5.8% (95% CI, 5.3--6.3) (position B) whereas with oocyte donation, it was 14.0% (95% CI, 10.3--17.7) (position C). When factors were combined along the tree, women with the highest risk of severe acute maternal morbidity were nulliparous women with either oocyte donation (14.7%; 95% CI, 10.3--19.1) (position D) or of sub-Saharan origin (12.2%, 95% CI, 6.8--17.6) (position E); these two subgroups represented 2.8% and 1.6% of the women in the JUMODA cohort, respectively.

![Factors present at the beginning of pregnancy.\
Classification and regression tree analysis: hierarchy of factors associated with severe acute maternal morbidity, number of women, and percentage of events at each node Reported for each subgroup: the rate of SAMM and its 95% CI, the number of women with SAMM/number of women included in this subgroup.](pone.0229612.g001){#pone.0229612.g001}

10.1371/journal.pone.0229612.t002

###### Risk factors for severe acute maternal morbidity in twin pregnancies, JUMODA cohort (N = 8823).

![](pone.0229612.t002){#pone.0229612.t002g}

                                                                                                                                At the beginning of pregnancy   At the end of pregnancy   
  ---------------------------------------------------------------------------- ------------------------------------------------ ------------------------------- ------------------------- ----------------
  Maternal age (years)                                                                                                                                                                    
                                                                               \<30                                             Reference                       Reference                 Reference
                                                                               \[30--35\[                                       1.1 (0.9--1.2)                  1.1 (0.9--1.3)            1.0 (0.9--1.3)
                                                                               \[35--40\[                                       0.9 (0.7--1.1)                  0.8 (0.7--1.1)            0.8 (0.6--1.0)
                                                                               ≥40                                              1.7 (1.3--2.2)                  1.3 (0.9--1.8)            1.2 (0.9--1.7)
  Body mass index before pregnancy (Kg.m-2)                                                                                                                                               
                                                                               \<18,5                                           1.1 (0.8--1.5)                  1.1 (0.8--1.5)            1.1 (0.8--1.6)
                                                                               \[18.5--24.9\]                                   Reference                       Reference                 Reference
                                                                               \[25--29.9\]                                     0.9 (0.7--1.1)                  0.9 (0.7--1.1)            0.8 (0.7--1.0)
                                                                               \[30--34.9\]                                     0.8 (0.5--1.1)                  0.8 (0.5--1.1)            0.7 (0.5--1.0)
                                                                               ≥35                                              0.7 (0.6--1.0)                  0.8 (0.5--1.4)            0.7 (0.4--1.3)
  Country of birth                                                                                                                                                                        
                                                                               Europe                                           Reference                       Reference                 Reference
                                                                               North Africa                                     1.2 (0.9--1.5)                  1.3 (0.9--1.7)            1.3 (0.9--1.6)
                                                                               Sub-Saharan Africa                               1.3 (1.0--1.8)                  1.6 (1.1--2.3)            1.4 (1.0--2.1)
                                                                               Other                                            1.4 (0.8--2.5)                  1.3 (0.6--2.8)            1.4 (0.7--2.9)
  Parity and previous caesarean                                                                                                                                                           
                                                                               Nulliparous                                      1.8 (1.5--2.1)                  1.6 (1.3--2.0)            1.5 (1.2--1.9)
                                                                               Parous without previous caesarean                Reference                       Reference                 Reference
                                                                               Parous with previous caesarean                   1.4 (1.0--1.8)                  1.3 (0.9--1.8)            1.3 (0.9--1.8)
  Preexisting hypertension                                                     1.2 (0.6--2.4)                                   1.1 (0.6--2.3)                  0.8 (0.4--1.6)            
  Preexisting insulin-treated diabetes                                         2.2 (1.1--4.3)                                   2.2 (1.1--4.4)                  1.6 (0.8--3.0)            
  Other preexisting chronic condition[\*\*](#t002fn003){ref-type="table-fn"}   1.1 (0.9--1.5)                                   1.0 (0.8--1.4)                  1.1 (0.8--1.5)            
  Mode of conception                                                                                                                                                                      
                                                                               Spontaneous                                      Reference                       Reference                 Reference
                                                                               Ovulation-inducting drugs alone                  1.2 (0.9--1.6)                  1.1 (0.8--1.4)            1.1 (0.8--1.4)
                                                                               In vitro fertilization with autologous oocytes   1.5 (1.2--1.8)                  1.3 (1.0--1.6)            1.3 (1.0--1.6)
                                                                               Oocyte donation                                  2.7 (2.0--3.5)                  2.0 (1.4--2.8)            1.7 (1.2--2.3)
  Chorionicity                                                                                                                                                                            
                                                                               Dichorionic                                      Reference                       Reference                 Reference
                                                                               Monochorionic                                    0.8 (0. 7--1.0)                 0.9 (0.8--1.2)            1.0 (0.8--1.2)
  Insulin-treated gestational diabetes                                         1.2 (0.8--1.7)                                   \-                              1.0 (0.7--1.6)            
  Gestational hypertension                                                     2.1 (1.6--2.7)                                   \-                              1.2 (0.9--1.7)            
  Non-severe preeclampsia                                                      2.9 (2.4--3.5)                                   \-                              2.5 (1.9--3.2)            
  Placenta praevia                                                             3.7 (2.4--5.7)                                   \-                              3.5 (2.3--5.3)            
  Twin-to-twin transfusion syndrome                                            0.7 (0.4--1.3)                                   \-                              0.9 (0.5--1.7)            
  Premature rupture of membranes                                               0.7 (0.5--0.9)                                   \-                              0.7 (0.5--1.0)            
  Macrosomia[\*\*\*](#t002fn004){ref-type="table-fn"}                          1.5 (1.2--1.8)                                   \-                              1.7 (1.3--2.1)            
  Maternity hospital:                                                                                                                                                                     
  Annual volume of twin deliveries                                                                                                                                                        
                                                                               \<50                                             0.7 (0.6--0.9)                  \-                        1.1 (0.7--1.6)
                                                                               \[50--99\]                                       0.8 (0.7--1.0)                  \-                        1.0 (0.8--1.2)
                                                                               ≥100                                             Reference                       \-                        Reference
  Level of care                                                                                                                                                                           
                                                                               I                                                0.4 (0.1--1.0)                  \-                        0.4 (0.1--1.4)
                                                                               II                                               0.7 (0.6--0.9)                  \-                        0.7 (0.5--1.0)
                                                                               III                                              Reference                       \-                        Reference

RR, relative risk; CI, confidence interval

\*Each relative risk is adjusted for all other variables in the column, multilevel multivariate Poisson regression model, with imputed data

\*\* Other preexisting chronic condition, defined by a binary variable as the presence of at least one of the following: non-insulin-treated diabetes, disease of the circulatory, respiratory, or digestive system, hematological, mental, liver, or autoimmune disease, venous thromboembolism, epilepsy, nephropathy, multiple sclerosis, neoplasia, HIV infection, or active hepatitis B or C

\*\*\* macrosomia defined as a birth weight ≥ 95th percentile of the distribution of birth weights in the JUMODA cohort

The second multivariate model included factors identified over the course of pregnancy; placenta praevia (aRR, 3.5, 95% CI, 2.3--5.3), non-severe preeclampsia (aRR, 2.5, 95% CI, 1.9--3.2), and macrosomia for either twin (aRR, 1.7, 95% CI, 1.3--2.1) were then risk factors for severe acute maternal morbidity ([Table 2](#pone.0229612.t002){ref-type="table"}). The second CART analysis, including the risk factors identified during pregnancy, showed that non-severe preeclampsia was the most discriminating factor (position A, [Fig 2](#pone.0229612.g002){ref-type="fig"}). In the absence of non-severe preeclampsia, the severe acute maternal morbidity rate was 5.2% (95% CI, 4.7--5.7) (position B), while with non-severe preeclampsia, it reached 15.2% (95% CI, 12.8--17.6) (position C). As we followed the \"non-severe preeclampsia\" branch to the terminal leaves of the tree, the highest risk of severe acute maternal morbidity was found in two subgroups of women with non-severe preeclampsia: those with oocyte donation (28.9%; 95% CI, 19.9--37.9) (position D) and those nulliparas born in sub-Saharan Africa (26.9%; 95% CI, 9.9--43.9) (position E); these subgroups accounted respectively for 1.1% and 0.3% of the women in the JUMODA cohort. Conversely, the women at lowest risk (3.8%; 95% CI, 3.2--4.4) were multiparous with none of the following events: non-severe preeclampsia, placenta praevia, or macrosomia (position F).

![Factors present at the beginning and arising during pregnancy.\
Classification and regression tree analysis: hierarchy of factors associated with severe acute maternal morbidity, number of women, and percentage of events at each node Reported for each subgroup: the rate of SAMM and its 95% CI, the number of women with SAMM/number of women included in this subgroup.](pone.0229612.g002){#pone.0229612.g002}

In the sensitivity analysis excluding severe acute maternal morbidity related to hypertensive complications, results were similar and notably non-severe preeclampsia remained a risk factor of severe acute maternal morbidity with a similar estimate for adjusted relative risk ([S3 Table](#pone.0229612.s003){ref-type="supplementary-material"}). In addition, CART analysis showed that non-severe preeclampsia remained the most discriminating factor for identifying women at higher risk of severe acute maternal morbidity ([S1 Fig](#pone.0229612.s005){ref-type="supplementary-material"}).

The sensitivity analysis including delivery-related characteristics identified the same risk factors as above. In addition, caesarean delivery was associated with a significantly higher risk of intra- or postpartum severe acute maternal morbidity, whether performed before (aRR, 1.3, 95% CI, 1.0--1.6) or during labor (aRR, 1.6, 95% CI, 1.2--1.9). Finally a gestational age at birth less than 37 weeks of gestation was associated with a significantly lower risk of intra- or postpartum severe acute maternal morbidity (aRR, 0.8, 95% CI, 0.7--0.9) ([S4 Table](#pone.0229612.s004){ref-type="supplementary-material"}).

Discussion {#sec008}
==========

Main findings {#sec009}
-------------

In women with twin pregnancies, the overall increased risk of developing severe acute maternal complications varies by subgroups of women. At the beginning of twin pregnancy, nulliparous women with oocyte donation were identified as those with the highest risk of severe acute maternal morbidity. At the end of pregnancy, two subgroups of women with a risk exceeding 25% of developing severe acute maternal morbidity were identified: those with both oocyte donation and non-severe preeclampsia, and nulliparas born in sub-Saharan Africa with non-severe preeclampsia.

Strengths and limitations {#sec010}
-------------------------

Our study has several strengths. It was a large population-based study including a substantial number of both twin pregnancies and of cases of severe acute maternal morbidity. The analysis of severe acute maternal morbidity was planned during the design of the JUMODA study, so that the data to characterize it were defined in advance and collected prospectively. The data collection method involving a manual review of the medical records of each woman provided detailed and accurate information on maternal and pregnancy characteristics, unlike data extracted from routine hospital databases in retrospective studies.

One limitation of this study is that the JUMODA cohort included only maternity units with more than 1500 annual deliveries. Although the twin deliveries included in the JUMODA study accounted for 75% of all twin deliveries in France over the study period, this could potentially mean that our results cannot be fully generalized to women giving birth in the smallest hospitals. However, the incidence of severe acute maternal morbidity we found here is similar to the one reported in another French population-based study including units of all sizes.^3^ Furthermore, despite more than 8800 women were included in this study, its statistical power for covering rare pathologies that might be severe acute maternal morbidity risk factors remains limited. Finally, the results of CART analyses would benefit from a validation in another cohort of twin pregnancies and are limited by the fact that not all clinical situations are represented in the final tree.

Interpretation {#sec011}
--------------

The most original result---and perhaps the most helpful for clinicians---is the characterization among this population of subgroups with various levels of risk of severe acute maternal morbidity, by CART analysis. This analysis is complementary to the standard epidemiologic study of risk factors by multivariate regression, but applies an approach that is more pragmatic than explanatory. By directly estimating the severe acute maternal morbidity rate in subgroups that combine multiple risk factors, it may help clinicians to advise women on the most appropriate place for delivery and to adapt their management throughout pregnancy by anticipating the occurrence of those adverse events.

At the beginning of pregnancy, we found that maternal birth in sub-Saharan Africa, preexisting insulin-treated diabetes, nulliparity and mode of conception were risk factors for severe acute maternal morbidity. Although these results are concordant with previous studies conducted in general populations of parturients or populations of singleton pregnancies, it is important to verify that these risk factors persist in this high-risk population \[[@pone.0229612.ref011]--[@pone.0229612.ref017]\]. CART analysis found that at the beginning of pregnancy oocyte donation is the most discriminating factor for severe acute maternal morbidity. This increased maternal risk in women with twin pregnancies after IVF contradicts some previous studies exploring this association \[[@pone.0229612.ref009],[@pone.0229612.ref018]--[@pone.0229612.ref020]\]. The latter, however, were limited by their inability to differentiate between spontaneous pregnancy and ovulation-inducing drugs alone and between in vitro fertilization with autologous and donated oocytes.

An unexpected result was the lack of association between severe acute maternal morbidity and maternal age. Wondering whether this result might be due to overadjustment when mode of conception and age were simultaneously included in the model, we conducted an analysis stratified by mode of conception. It confirmed the lack of association, regardless of the mode of conception (data not shown).

At the end of pregnancy, the CART analysis highlighted that even in subgroups of twin pregnancies with the lowest risk, the rate of severe acute maternal morbidity still remains twice the rate usually reported in singleton pregnancies \[[@pone.0229612.ref003],[@pone.0229612.ref009]--[@pone.0229612.ref012]\]. We found that the most discriminating factor for the occurrence of severe acute maternal morbidity was non-severe preeclampsia, which has been previously reported as a risk factor for severe acute maternal morbidity in general populations of parturients and in singleton pregnancies \[[@pone.0229612.ref021],[@pone.0229612.ref022]\]. We confirm here that this association also exists among twin pregnancies. This result might appear trivial, since non-severe preeclampsia could be considered just a step within the morbidity continuum of hypertensive-related complications. Nonetheless, it is noteworthy that when we excluded severe acute maternal morbidity events due to hypertensive complications from the outcomes, results of multivariate and CART analyses remained similar. This suggests that non-severe preeclampsia is a risk factor for other causes of severe acute maternal morbidity than hypertensive complications. Moreover, the CART analysis provided here shows that among women with twin pregnancies and non-severe preeclampsia, additional risk factors boost the risk of a severe acute maternal morbidity up to rates above 25%.

The identification of some modifiable risk factors can help improve the management of women with twin pregnancy. Preventive care can start during the preconceptional period. The high maternal risk in twin pregnancies after in vitro fertilization constitutes an argument for limiting the number of embryos transferred to a single embryo in order to prevent medically-induced multiple pregnancies and associated severe maternal morbidity. This is particularly important in case of oocyte donation, which must be a reasoned practice. An increased risk of severe acute maternal morbidity associated with maternal country of birth, another identified risk factor, may also be indirectly modifiable. Some previous studies have reported an increased risk of severe hypertensive complications in migrant women, in particular from sub-Saharan Africa \[[@pone.0229612.ref011],[@pone.0229612.ref023],[@pone.0229612.ref024]\]. Among suggested hypotheses are genetic factors \[[@pone.0229612.ref025]\] but also differential prenatal care \[[@pone.0229612.ref026], [@pone.0229612.ref027],[@pone.0229612.ref028]\]. Thus if the association between maternal country of birth and severe acute maternal morbidity reflects differential prenatal care, this risk factor could be changed by improving the quality of care for these vulnerable women.

Conclusion {#sec012}
==========

About one in 17 women with a twin pregnancy will develop severe acute maternal morbidity overall, and this proportion rises up to more than a quarter in some particular subgroups of women. These results have implications for clinical practice. They will help identifying modifiable risk factors, personalizing information and improving shared decision regarding prenatal and delivery care for women with twin pregnancies, according to their individual profile.
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Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <https://clicktime.symantec.com/34uYZEGrViwwJiXZ15MZ2ch6H2?u=http%3A%2F%2Fjournals.plos.org%2Fplosone%2Fs%2Fdata-availability%23loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <https://clicktime.symantec.com/3VUWv2qA9KnXzUZXsdCzx4V6H2?u=http%3A%2F%2Fjournals.plos.org%2Fplosone%2Fs%2Fdata-availability%23loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

The data underlying the findings cannot be made freely available because of ethical and legal restrictions. This is because the present study includes an important number of variables that, together, could be used to re-identify the participants based on a few key characteristics and then be used to have access to other personal data. Therefore, the French National Data Safety Authority (CNIL) strictly forbids making such data freely available. However, they can be obtained upon request from the JUMODA steering committee. Readers may contact: <diane.korb@inserm.fr> or <epope@inserm.fr> to request the data.

5\. One of the noted authors is a group or consortium: JUmeaux MODe d'Accouchement (JUMODA) study group and the Groupe de Recherche en Obstétrique et Gynécologie (GROG)

In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

Individual collaborators of JUMODA group and GROG are not co-authors of this manuscript.

We have added in the acknowledgments section the individual collaborators of JUMODA group and GROG and their affiliations. In supplementary file, we added the lead author for these groups along with contact email address.

Response to the Reviewers

Reviewer \#1: This manuscript uses a large population-based study of twin pregnancies \"Jumonda\" to identify risk factors for severe maternal morbidity and was planned prospectively. The primary outcome was a composite of including maternal death, severe hemorrhage (defined by need for second line therapy), transfusion \>=units of pRBCs, uterine artery embolization, and several other severe adverse outcomes. They identified two subgroups of women with a \>25% risk of developing severe acute maternal morbidity: those with both oocyte donation, non-severe preeclampsia, and nulliparas born in Sub-Saharan Africa with non-severe preeclampsia.

We thank the Reviewer for his/her comment.

Reviewer \#2:

1\. This is a potential wonderful paper. I am afraid I have major problems with the definition of severe morbidity.

Pre ecclampsia requiring delivery is certainly serious but NOT always a severe morbid event.

We agree with the Reviewer that preeclampsia can reflect different steps within the morbidity continuum of hypertension-related complications.

The definition of severe preeclampsia in our study was the one retained in the EPIMOMS study. The EPIMOMS definition of severe maternal morbidity was obtained via an extensive national Delphi expert consensus process, with a panel of professionals including obstetricians, midwives, anaesthesiologists/intensive care specialists, and public health specialists. The process followed a Delphi-Rand design and consisted of two rounds followed by a final plenary session. The level of consensus for each round was fixed at 70%. Several published analyses were conducted with this definition confirming the recognition of its validity. (1-5)

In this multicriteria definition of severe maternal morbidity, severe preeclampsia can be defined through various criteria that indicate maternal : either a preeclampsia which indicated an induction of a preterm delivery before 32 gestational weeks for a maternal indication; or a preeclampsia associated with eclampsia, HELLP syndrome, or placental abruption; or responsible for a severe organ dysfunction (as per Epimoms specific definitions for each dysfunction): respiratory dysfunction, renal dysfunction, hepatic dysfunction.

To define severe (for the mother) preeclampsia apart from the aforementioned preeclampsia complications, criterion retained was the gestational age at induced delivery and not proteinuria or blood pressure cut-offs, because thresholds are not consensual. Severe preeclampsia remote from term is challenging and requires assessment of the benefit-risk balance for the fetus and for the mother between an expectant management and an induced preterm delivery. Before 32 gestational weeks if an induced preterm delivery was decided for a main maternal indication, this can only be for a severe event compromising maternal health allowing to consent for neonatal morbidity induced by prematurity.

Furthermore, we performed a sensitivity analysis after exclusion of severe acute maternal morbidity cases only due to hypertensive complications (n= 19 women) and our results were unchanged (S4A Table), as mentioned in the methods section line 137 to 142 and in the results section line 247 to 252.

Therefore, we believe that SAMM events due to severe preeclampsia were always severe morbid events and do not compromise the validity of our results.

2\. In a large network Criteria to admit to an ICU will not all be the same and thus potential for bias.

We agree with the Reviewer that intensive care units (ICU) admission can depend on several factors, including the organization of the health care system and the accessibility and availability of ICU. (6,7) However, maternal admission to ICU has been considered by many authors as a ''proxy'' for reasonably assessing SAMM. (8-16) In France, rates, causes and severity of maternal admissions to intensive care units were analyzed in a recent study and showed a decrease in the rate of maternal ICU admissions from 2010 to 2014, but that the admitted mothers presented more severe clinical conditions, requiring more often resuscitation procedures and techniques provided in ICU. (17) These results suggest that admission to ICU increasingly reflects severe maternal morbidity.

Moreover in our study, among the 121 women admitted to ICU, only 16 did not have any other criterion of the composite definition of SAMM, and indications of admission to ICU confirm the severity of this event (table below).

Therefore, we do not believe that inclusion of the ICU admission criterion could have resulted in a potential bias.

Table: Indications of admission to ICU in JUMODA study

Indications of admission to ICU (not exclusive) N (%)

N=121

Severe postpartum hemorrhage 75 (62.0)

Eclampsia 5 (4.1)

HELLP syndrom 24 (19.8)

Other hypertensive complications 7 (5.8)

Respiratory dysfunction 5 (4.1)

Severe infection 5 (4.1)

Pulmonary embolism 3 (2.5)

Hepatic dysfunction 3 (2.5)

Others 10 (8.3)

3\. This has the potential for a significant impact please try to find another channel is Tiffany and why except it if I am open even though yours was conducted using a a delfi

Can you be more strict in your defn of SMM and redo ? It will be more meaningful for everyone

For the reasons provided in response to previous comments, we believe that the Epimoms definition of SAMM obtained through a national consensus of experts is valid to define events of severe maternal morbidity and that it is not necessary to reanalyze the data with a more strict definition of SAMM.

Our results will be unchanged with a definition of SAMM excluding preeclampsia and admission to ICU.
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